Microbiome research — NIH Funding Overview
Reviewed by Dr. Meng ZhaoLast reviewed June 9, 2026Data refreshed September 5, 2026Editorial standards
Microbiome research at NIH continues to mature beyond the original Human Microbiome Project. Active areas include the gut-brain axis, microbiome-immune interactions, oral and vaginal microbiomes, fecal microbiota transplantation, and microbiome-targeted therapeutics. Multiple ICs fund work depending on disease focus.
Funding snapshot
Award data on this page reflects a snapshot of NIH RePORTER records last refreshed on September 5, 2026. For live numbers, use the interactive trends view.
Why this matters now
Microbiome science has translated into FDA-approved therapeutics (e.g., Vowst, Rebyota for recurrent C. difficile in 2022–23) and ongoing trials in IBD, immune-mediated disease, and oncology immunotherapy response. NIH funding now emphasizes mechanistic and translational work over census-style cataloging.
How NIH funds this area
Mechanisms span R01, R21, U01, U19, and Common Fund initiatives. NIDDK, NIAID, NCI, and NHLBI are major funders depending on disease scope. Data below covers all NIH awards mentioning microbiome in title, abstract, or terms.
How to use this funding brief
Use this page to determine whether recent awards show durable mechanistic or translational momentum rather than another descriptive sequencing wave. Narrow by body site, disease, and intervention type before drawing conclusions from the broad microbiome total.
Official source: NIH Common Fund: Human Microbiome research
Search tactics
- Search "gut microbiome", "oral microbiome", or "vaginal microbiome" for site-specific research.
- For therapeutic applications, search "fecal microbiota transplantation" or "live biotherapeutic".
- Microbiome-immunotherapy intersection (NCI funding) has grown rapidly post-2020.
What the data shows
- Funding peaked in FY2025 at $1.5B. The FY2025 total of $1.5B is +25% versus FY2021.
- The number of awards fell about 7% in FY2025 even as total dollars grew — funding is concentrating in fewer, larger awards.
- About 83% of FY2026 dollars so far are non-Type-1 award actions, including competing renewals, supplements, non-competing continuations, and institutional changes. This is a descriptive record mix, not a measure of renewal activity alone.
- The average FY2025 award was $702K, and R01 was the most common mechanism in the recent window.
Editorial read
Microbiome funding grew about 25% from FY2021 to a FY2025 peak, but the more useful signal is qualitative: recent awards skew toward mechanistic and interventional designs — engineered consortia, defined communities, microbiome-derived therapeutics — rather than the descriptive sequencing surveys that built the field. Proposals framed as another association study face a much higher bar than the totals suggest.
Yearly NIH Awards for Microbiome research
Counts and total funding per fiscal year from NIH RePORTER. Recent fiscal years may understate final totals because of reporting lag.
| Fiscal Year | Project Count | Total Funding | Avg Award |
|---|---|---|---|
| FY2021 | 1,973 | $1,205,509,055 | $611,003 |
| FY2022 | 2,123 | $1,366,718,352 | $643,767 |
| FY2023 | 2,221 | $1,402,344,546 | $631,402 |
| FY2024 | 2,308 | $1,466,878,154 | $635,562 |
| FY2025 | 2,148 | $1,508,041,499 | $702,068 |
| FY2026 | 1,599 | $994,235,657 | $621,786 |
Open the full interactive trends view for Microbiome research →
Top NIH Institutes (last 90 days)
Which NIH institutes funded the most Microbiome projects in the most recent 90-day window.
| Institute | Awards (90d) | Funding (90d) |
|---|---|---|
| NIH | 485 | $320,656,850 |
| VA | 15 | $0 |
Common Activity Codes (last 90 days)
Which grant mechanisms (R01, R21, U01, P30, etc.) appeared most often for Microbiome in the recent period.
Most Active Institutions (last 90 days)
Universities and research organizations with the most Microbiome awards in the most recent 90-day window.
- UNIVERSITY OF COLORADO DENVER — 15 awards
- UNIVERSITY OF CHICAGO — 15 awards
- EMORY UNIVERSITY — 14 awards
- UNIVERSITY OF PITTSBURGH AT PITTSBURGH — 11 awards
- UNIV OF NORTH CAROLINA CHAPEL HILL — 11 awards
- UNIVERSITY OF CALIFORNIA, SAN DIEGO — 10 awards
- BAYLOR COLLEGE OF MEDICINE — 9 awards
- UNIVERSITY OF ALABAMA AT BIRMINGHAM — 9 awards
Recently Awarded Microbiome research Grants
Twelve most recent awards mentioning Microbiome, drawn from NIH RePORTER. Click through to Find PIs for the full investigator search.
Using miRNA to identify new therapeutic pathways for dilated cardiomyopathy
5R00HL165099-04Francesca Briganti · UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA · $247,482 · awarded Aug 28, 2026 · R00SUMMARY Dilated cardiomyopathy (DCM) associated heart failure is a leading cause of death and new therapeutic strategies are needed. Pathogenic variants in over 50 genes contribute to DCM, but the molecular mechanisms of disease are poorly understood. Much remains to be done to understand disease mechanisms and translate the basic science into therapeutic…
The Role of Chemical Exposures in Alzheimer's Disease (AD) and its Trajectory
3U01AG088562-03S3Rima Kaddurah-Daouk · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON, TX · $27,000 · awarded Aug 28, 2026 · U01ABSTRACT It has become increasingly clear that environmental exposures, the genome, gut microbiome, diet, and lifestyle all affect an individual’s metabolic state contributing to brain health and disease, including Alzheimer’s disease (AD) and AD-related dementia (ADRDs). Our AD Metabolomics Consortium (ADMC), in collaboration with the AD Neuroimaging…
The transactivation of human endogenous retrovirus (HERV)-K by oncogenic virus in HIV+ patients and development of targeted therapies
1R01DE035802-01A1Zhiqiang Qin · UNIV OF ARKANSAS FOR MED SCIS, AR · $647,465 · awarded Aug 28, 2026 · R01Abstract Kaposi’s Sarcoma-associated Herpesvirus (KSHV) is the etiologic agent of several human cancers, including Kaposi’s Sarcoma (KS) and Primary Effusion Lymphoma (PEL), which preferentially arise in immunocompromised patients and lack of effective therapeutic options. KS also represents one of common oral cancers in these patients. Human Endogenous…
Topical Vitamin D and Periodontal Disease
2R01DE028883-06GILL DIAMOND · UNIVERSITY OF LOUISVILLE, KY · $695,566 · awarded Aug 28, 2026 · R01Project Summary Periodontitis is a highly prevalent chronic inflammatory disease that leads to destruction of gingival tissues, periodontal ligament, and alveolar bone, and contributes to systemic inflammatory comorbidities. Despite its clinical significance, current treatments primarily target bacterial biofilms and fail to address the dysregulated host…
An experimental platform to investigate the role of polymicrobial synergy in oral inflammatory dysbiosis
1R01DE035850-01Justin Merritt · OREGON HEALTH & SCIENCE UNIVERSITY, OR · $557,951 · awarded Aug 27, 2026 · R01PROJECT SUMMARY Human inflammatory dysbiotic diseases exhibit a characteristic dysregulation of host inflammatory control mechanisms in response to the local microbial ecology at disease sites. Paradoxically, it is the host immune response to these “inflammophilic” communities that is responsible for sustaining their persistence as well as triggering most of…
Ultra-processed Foods, Diet Quality, and Cardiometabolic Health: An Inter-disciplinary Trans-Atlantic Collaborative Project
5R01DK120870-07Qi Sun · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH, MA · $815,697 · awarded Aug 27, 2026 · R01Project Summary/Abstract Ultra-processed foods (UPFs) prevail in the U.S. and account for ~60% total energy consumed by Americans. Fast-accumulating evidence from epidemiological studies shows unequivocal evidence that total UPF intake is linked to detrimental health outcomes. In thus far the only randomized, domiciled trial by Hall et al, diets enriched…
Core Grant for Vision Research
5P30EY008098-38John Ash · UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA · $795,000 · awarded Aug 27, 2026 · P30SUMMARY – OVERALL COMPONENT This P30 renewal proposal requests continued funding to support the operation of six resource modules within the Vision Institute (VI) at Mercy Pavilion of the University of Pittsburgh. The VI provides a home base for the basic and clinical vision research for ~30 vision scientists in four departments at the University of…
The Role of Chemical Exposures in Alzheimer's Disease (AD) and its Trajectory
3U01AG088562-03S1Rima Kaddurah-Daouk · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON, TX · $81,000 · awarded Aug 27, 2026 · U01ABSTRACT It has become increasingly clear that environmental exposures, the genome, gut microbiome, diet, and lifestyle all affect an individual’s metabolic state contributing to brain health and disease, including Alzheimer’s disease (AD) and AD-related dementia (ADRDs). Our AD Metabolomics Consortium (ADMC), in collaboration with the AD Neuroimaging…
The Role of Chemical Exposures in Alzheimer's Disease (AD) and its Trajectory
3U01AG088562-03S2Rima Kaddurah-Daouk · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON, TX · $81,000 · awarded Aug 27, 2026 · U01ABSTRACT It has become increasingly clear that environmental exposures, the genome, gut microbiome, diet, and lifestyle all affect an individual’s metabolic state contributing to brain health and disease, including Alzheimer’s disease (AD) and AD-related dementia (ADRDs). Our AD Metabolomics Consortium (ADMC), in collaboration with the AD Neuroimaging…
CANCAN-HARVARDTHCHAN
3OT2CA278654-01S3Sheng Hui · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH, MA · $307,052 · awarded Aug 27, 2026 · OT2Background Cancer cachexia (CC) is a systemic, metabolic wasting syndrome featuring body weight loss due to skeletal muscle and adipose tissue wasting. CC is suffered by ~80% of cancer patients that causes reduced performance status, intolerance to chemotherapy, and increased mortality. This debilitating condition is poorly understood and has no effective…
CANCAN - Harvard
3OT2CA278689-01S3NORBERT PERRIMON · HARVARD MEDICAL SCHOOL, MA · $473,923 · awarded Aug 26, 2026 · OT2Background Cancer cachexia (CC) is a systemic, metabolic wasting syndrome featuring body weight loss due to skeletal muscle and adipose tissue wasting. CC is suffered by ~80% of cancer patients that causes reduced performance status, intolerance to chemotherapy, and increased mortality. This debilitating condition is poorly understood and has no effective…
University of Miami IBD Genetic Research Center: Understanding the Genetic Architecture of IBD in the South Florida community
3U01DK134201-05S1Jacob McCauley · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE, FL · $148,427 · awarded Aug 26, 2026 · U01PROJECT SUMMARY Inflammatory bowel disease (IBD) is a common and devastating immune-mediated disease in which the mucosal immune system abnormally recognizes the intestinal bacterial flora leading to chronic inflammation. Approximately, 1% of the US population is affected. The causes of Crohn's disease (CD) and ulcerative colitis (UC) lie in the interplay…
Explore further
Related topics
Related guides
Background reading on grant strategy and how to interpret the numbers above for Microbiome research.
NIH R01 Grant: The Complete Guide to the Gold Standard of Research Funding
Everything researchers need to know about the NIH R01 — eligibility, application components, review process, scoring, pay lines, timeline, and strategies for first-time applicants.
Understanding NIH Grant Trends: What the Data Tells You and What It Does Not
A methodological guide to reading NIH funding trends responsibly, comparing years, and avoiding false conclusions from noisy data.
Understanding NIH Funding Trends: How to Position Your Research for Success
How to use NIH funding patterns to position a project, choose institutes, and avoid overreading noisy trend shifts.